Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Cerity Partners LLC

Cerity Partners LLC cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 51,687 shares of the medical equipment provider’s stock after selling 4,877 shares during the period. Cerity Partners LLC’s holdings in Hologic were worth $3,193,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Beverly Hills Private Wealth LLC grew its position in Hologic by 3.6% during the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock valued at $320,000 after acquiring an additional 180 shares during the period. Allworth Financial LP grew its holdings in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares during the period. Dark Forest Capital Management LP increased its position in Hologic by 7.9% during the 4th quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider’s stock worth $220,000 after purchasing an additional 223 shares in the last quarter. Baker Avenue Asset Management LP raised its holdings in Hologic by 0.5% in the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider’s stock valued at $3,031,000 after buying an additional 225 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on HOLX shares. Stephens dropped their price objective on shares of Hologic from $77.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, May 13th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and increased their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Mizuho boosted their price objective on Hologic from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday. Evercore ISI upped their price target on Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a report on Tuesday, July 8th. Finally, Morgan Stanley lowered their price target on shares of Hologic from $77.00 to $65.00 and set an “equal weight” rating for the company in a report on Monday, May 5th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and an average target price of $77.33.

Hologic Stock Performance

Shares of HOLX opened at $63.99 on Friday. The stock has a market capitalization of $14.26 billion, a PE ratio of 27.00, a price-to-earnings-growth ratio of 2.35 and a beta of 0.55. The business’s fifty day moving average price is $62.46 and its 200 day moving average price is $63.25. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the firm posted $1.03 EPS. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director owned 5,445 shares of the company’s stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.88% of the stock is owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.